|
|
| (22 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | {{pnc}}__NOTOC__ | | {{pnc}}__NOTOC__ |
| | | | |
| − | ===Antibody-dependent enhancement===
| + | {{ft|I}} |
| − | {{tp|p=32361326|t=2020. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.|pdf=|usr=008}} | + | *'''[[Antibody-dependent enhancement ]]''' |
| − | {{ttp|p=32504046|t=2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.|pdf=|usr=007}}
| + | *'''[[Herd immunity ]]''' |
| − | {{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}}
| + | *'''[[Neutralizing antibodies ]]''' |
| − | {{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}}
| + | *'''[[Innate immunology ]]''' |
| − | {{ttp|p=31826992|t=2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |pdf=|usr=}}''antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.''
| + | *'''[[Integrative work ]]''' ''reviews, intertopic'' |
| − | {{ttp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}} ade
| + | *'''[[Cov2 modulates the immune system ]]''' |
| − | {{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
| + | *'''[[Immune cell subpopulations ]]''' |
| − | {{tp|p=32303697|t=ä. Will we see protection or reinfection in COVID-19?|pdf=|usr=}}
| + | *'''[[T cell exhaustion ]]''' |
| − | {{tp|p=32438257|t=2020. SARS-CoV-2 and enhancing antibodies |pdf=|usr=}}
| + | *'''[[NK cells ]]''' |
| − | {{ttp|p=32408068|t=2020. What about the original antigenic sin of the humans versus SARS-CoV-2?|pdf=|usr=}}''the term «original antigenic sin» (OAS) was coined by T. Francis Jr at the Michigan University in the late 1950s to describe patterns of antibody response to influenza vaccination...''
| + | |
| − | {{tp|p=32436320|t=2020. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506725|t=2020. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.|pdf=|usr=007}}
| + | |
| | | | |
| − | | + | *'''[[MDSC myeloid-derived suppressor cells]] |
| − | ===Herd immunity===
| + | *'''[[Antiviral immune response ]]''' |
| − | {{tp|p=32438622|t=2020. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic.|pdf=|usr=007}}
| + | *'''[[Antiviral mediators ]]''' |
| − | {{tp|p=32391855|t=2020. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.|pdf=|usr=007}}
| + | *'''[[Immunopathology ]]''' |
| − | {{tp|p=32510562|t=2020. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge.|pdf=|usr=007}}
| + | *'''[[Secondary autoimmunity ]]''' |
| − | {{tp|p=32418947|t=2020. Does immune privilege result in recovered patients testing positive for COVID-19 again?|pdf=|usr=007}}
| + | *'''[[Thymus, Immunosenescence ]]''' |
| − | {{tp|p=32372779|t=2020. Do you become immune once you have been infected?|pdf=|usr=}}
| + | *'''[[Eosinophils ]]''' |
| − | | + | *'''[[Microbiome ]]''' |
| − | ===Neutralizing antibodies===
| + | *'''[[Pneumococcal synergism]]''' -new- |
| − | {{tp|p=32454513|t=2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection.|pdf=|usr=007}}
| + | *'''[[Bio-misc ]]''' ''on topic biology papers which cannot be indexed by title'' |
| − | {{tp|p=32454512|t=2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.|pdf=|usr=007}}
| + | *'''[[Hematology ]]''' |
| − | {{tp|p=32497196|t=2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.|pdf=|usr=007}}
| + | *'''[[Cytokine_storm,_hemophagocytic_lymphohistiocytosis,_macrophage_activation_syndrome|Cytokine storm ]]''' |
| − | {{ttp|p=32073157|t=2020. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus?associated illnesses |pdf=|usr=}}
| + | *'''[[Candidate_Compounds_Covid19 |Immunopharmacology ]]''' |
| − | | + | *'''[[Diagnosis_(Laboratory) |Clinical Laboratory Dx]]''' |
| − | ===Innate sensing===
| + | |
| − | {{ttp|p=32291557|t=ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |pdf=|usr=}}
| + | |
| − | {{tp|p=32198201|t=2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors |pdf=|usr=}}
| + | |
| − | {{tp|p=32374430|t=2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32361001|t=ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}}
| + | |
| − | {{ttp|p=32407669|t=ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32456409|t=2020. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32156572|t=2020. Viroporins and inflammasomes: A key to understand virus-induced inflammation |pdf=|usr=}}
| + | |
| − | | + | |
| − | ===integrative work===
| + | |
| − | *[https://www.cell.com/action/showPdf?pii=S1074-7613%2820%2930183-7 rev. on covid immunology] | + | |
| − | {{tp|p=32205856|t=2020. COVID-19 infection: the perspectives on immune responses |pdf=|usr=}}
| + | |
| − | {{tp|p=32359396|t=ä. A Dynamic Immune Response Shapes COVID-19 Progression |pdf=|usr=}}
| + | |
| − | {{tp|p=C7064018|t=ä. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses |pdf=|usr=}}
| + | |
| − | {{ttp|p=C7200337|t=ä. Immunology of COVID-19: current state of the science |pdf=|usr=}}
| + | |
| − | {{tp|p=32505227|t=2020. Immunology of COVID-19: Current State of the Science.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469225|t=2020. COVID-19 and the immune system.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32436629|t=2020. High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507543|t=2020. Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32504757|t=2020. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493812|t=2020. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470151|t=2020. The perplexing question of trained immunity versus adaptive memory in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472706|t=2020. The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32213336|t=ä. SARS-CoV-2: virus dynamics and host response |pdf=|usr=}}
| + | |
| − | {{tp|p=32437933|t=2020. Viral dynamics in asymptomatic patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32407836|t=2020. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32498686|t=2020. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32514817|t=2020. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | ===covid modulates the immune system===
| + | |
| − | {{tp|p=32364527|t=2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32172672|t=2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses |pdf=|usr=}}
| + | |
| − | {{tp|p=32315725|t=ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{ttp|p=32355328|t=ä. Impaired interferon signature in severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32375560|t=2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32376308|t=ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
| + | |
| − | {{ttp|p=32236983|t=2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{ttp|p=32286536|t=ä. Coronaviruses hijack the complement system |pdf=|usr=}}''host complement activator MASP2 as a target of the N protein of all three viruses''
| + | |
| − | {{tp|p=32463803|t=2020. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492165|t=2020. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32514592|t=2020. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32456696|t=2020. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | ===immune cell subpopulations===
| + | |
| − | {{tp|p=32282871|t=ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32325421|t=2020. Increased expression of CD8 marker on T-cells in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
| + | |
| − | {{tp|p=32346099|t=ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32228226|t=2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32196410|t=2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune changes in patients with viral pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32333914|t=ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia |pdf=|usr=}}
| + | |
| − | {{tp|p=32344320|t=ä. The clinical course and its correlated immune status in COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32325129|t=ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32283159|t=ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32227123|t=ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32343510|t=2020. COVID-19: are T lymphocytes simply watching?|pdf=|usr=}}
| + | |
| − | {{tp|p=32379887|t=ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32297671|t=2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32352397|t=2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study |pdf=|usr=}}
| + | |
| − | {{tp|p=32379199|t=2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes |pdf=|usr=}}
| + | |
| − | {{tp|p=32296069|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}}
| + | |
| − | {{tp|p=32407057|t=2020. Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32297828|t=2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32370466|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32114745|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
| + | |
| − | {{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32376308|t=2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32458561|t=2020. Lymphopenia in COVID-19: Therapeutic opportunities.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420610|t=2020. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470153|t=2020. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474608|t=2020. Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32483488|t=2020. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | ===t cell exhaustion===
| + | |
| − | {{tp|p=32249845|t=ä. Fighting COVID-19 exhausts T cells |pdf=|usr=}}
| + | |
| − | {{tp|p=32479985|t=2020. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{ttp|p=32203188|t=ä. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32203186|t=ä. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32203188|t=2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32203186|t=2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32414395|t=2020. COVID-19: room for treating T cell exhaustion?|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | ===nk cells===
| + | |
| − | {{tp|p=32382127|t=ä. NKG2A and COVID-19: another brick in the wall |pdf=|usr=}}
| + | |
| − | {{tp|p=32344314|t=2020. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | ===plasmacytoid dendritic cells===
| + | |
| − | {{tp|p=32298486|t=2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19) |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | ===antiviral immune response===
| + | |
| − | {{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32353870|t=2020. The many faces of the anti-COVID immune response |pdf=|usr=}}
| + | |
| − | {{tp|p=32358956|t=ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=31981224|t=2020. Coronavirus infections and immune responses |pdf=|usr=}}
| + | |
| − | {{tp|p=32198005|t=2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic |pdf=|usr=}}
| + | |
| − | {{tp|p=32284614|t=ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32355329|t=ä. SARS-CoV-2-reactive T cells in patients and healthy donors |pdf=|usr=}}
| + | |
| − | {{tp|p=32346091|t=ä. Neutralizing antibody response in mild COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32356908|t=2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis |pdf=|usr=}}
| + | |
| − | {{ttp|p=32343415|t=2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32330332|t=2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32267987|t=2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS |pdf=|usr=}}
| + | |
| − | {{tp|p=32348715|t=2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32382126|t=ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32200654|t=2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32476607|t=2020. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449333|t=2020. (+)Ability of the immune system to fight viruses highlighted by cytometry and TCR clonotype assessments: lessons taken prior to COVID-19 virus pandemic outbreak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32430094|t=2020. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32467617|t=2020. Serum IgA, IgM, and IgG responses in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32467616|t=2020. More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32463434|t=2020. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398307|t=2020. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425634|t=2020. The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32383183|t=2020. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.|pdf=|usr=008}}{{tp|p=32521002|t=2020. Antibody profiles in mild and severe cases of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399213|t=2020. Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | ===antiviral mediators===
| + | |
| − | {{tp|p=32422144|t=2020. Perforin and resistance to SARS coronavirus 2.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | ===mediators===
| + | |
| − | {{tp|p=32360285|t=ä. Type I IFN immunoprofiling in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32376393|t=ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |pdf=|usr=}}
| + | |
| − | {{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}}
| + | |
| − | {{tp|p=30715745|t=2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study |pdf=|usr=}}
| + | |
| − | {{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | {{ttp|p=32421281|t=2020. Is there relationship between SARS-CoV 2 and the complement C3 and C4?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437622|t=2020. Complement Activation During Critical Illness: Current Findings and an Outlook in the Era of COVID-19.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | ===immunopathology===
| + | |
| − | {{tp|p=32371101|t=ä. The correlation between SARS-CoV-2 infection and rheumatic disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32205186|t=2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!|pdf=|usr=}}
| + | |
| − | {{tp|p=32308263|t=2020. CoViD-19 Immunopathology and Immunotherapy |pdf=|usr=}}
| + | |
| − | {{tp|p=32320677|t=ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure |pdf=|usr=}}
| + | |
| − | {{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32282863|t=ä. Molecular immune pathogenesis and diagnosis of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32321823|t=2020. COVID-19: an Immunopathological View |pdf=|usr=}}
| + | |
| − | {{tp|p=32273594|t=ä. COVID-19: immunopathology and its implications for therapy |pdf=|usr=}}
| + | |
| − | {{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}}
| + | |
| − | {{ttp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}}
| + | |
| − | {{tp|p=32423059|t=2020. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485101|t=2020. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423917|t=2020. COVID-19 as an Acute Inflammatory Disease.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32512289|t=2020. Neutralizing antibodies mediate virus-immune pathology of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398875|t=2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32391668|t=2020. [Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32498376|t=2020. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460357|t=2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32492530|t=2020. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32389590|t=2020. COVID-19: Unanswered questions on immune response and pathogenesis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32422146|t=2020. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32521376|t=2020. SARS-CoV-2 (Covid-19): Interferon-epsilon may be responsible of decreased mortality in females.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | | + | |
| − | ===secondary autoimmunity===
| + | |
| − | {{tp|p=32292901|t=2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity |pdf=|usr=}}
| + | |
| − | {{tp|p=32220633|t=2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?|pdf=|usr=}}
| + | |
| − | {{tp|p=32315487|t=2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19 |pdf=|usr=}}
| + | |
| − | {{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}}
| + | |
| − | {{tp|p=32389543|t=ä. COVID-19 and molecular mimicry: The Columbus? egg?|pdf=|usr=}}
| + | |
| − | {{tp|p=32444414|t=2020. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | ===Thymus===
| + | |
| − | {{tp|p=32340873|t=ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype |pdf=|usr=}}
| + | |
| − | {{tp|p=32317217|t=ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | ===Eosinopenia, Eosinophilia===
| + | |
| − | {{tp|p=32368728|t=ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study |pdf=|usr=}}
| + | |
| − | {{tp|p=32344056|t=ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |pdf=|usr=}}
| + | |
| − | {{tp|p=32369190|t=2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series |pdf=|usr=}}
| + | |
| − | {{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32390402|t=2020. SARS-CoV-2 and Eosinophilia.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | | + | |
| − | ===microbiome===
| + | |
| − | {{tp|p=32497191|t=2020. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza.|pdf=|usr=007}}
| + | |
| − | {{ttp|p=32426999|t=2020. Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | ===008===
| + | |
| − | | + | |
| − | {{tp|p=32525657|t=2020. Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32463221|t=2020. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32503680|t=2020. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32503668|t=2020. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32412156|t=2020. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32398307|t=2020. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32379368|t=2020. Gastrointestinal effects of an attempt to "disinfect" from COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32398162|t=2020. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32498696|t=2020. COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32461409|t=2020. Sanitizer aerosol-driven ocular surface disease (SADOSD)-A COVID-19 repercussion?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519263|t=2020. India's COVID-19 Testing Strategy: Why Pediatric Hospitals Need to Focus More on ILI than SARI?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32277747|t=2020. A Low-cost Solution for Retro-fitment of HEPA Filter in Healthcare Facilities Providing Care to COVID-19 Patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32381129|t=2020. Dealing with skin reactions to gloves during the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32456749|t=2020. Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32408923|t=2020. Facepiece filtering respirators with exhalation valve should not be used in the community to limit SARS-CoV-2 diffusion.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32459123|t=2020. Mechanistic inferences from clinical reports of SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32474804|t=2020. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32468178|t=2020. Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399895|t=2020. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32492530|t=2020. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32470604|t=2020. A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32464271|t=2020. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425643|t=2020. Association of inflammatory markers with the severity of COVID-19: A meta-analysis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425634|t=2020. The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32422376|t=2020. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437933|t=2020. Viral dynamics in asymptomatic patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437934|t=2020. Use of anakinra in severe COVID-19: a case report.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32497811|t=2020. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32497810|t=2020. HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32504146|t=2020. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32500199|t=2020. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32458044|t=2020. Inside the lungs of COVID-19 disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32397684|t=2020. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32397010|t=2020. N95 respirator associated pressure ulcer amongst COVID-19 health care workers.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32396265|t=2020. The prevalence, characteristics, and related factors of pressure injury in medical staff wearing personal protective equipment against COVID-19 in China: A multicentre cross-sectional survey.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32385523|t=2020. IL-6 may be a good biomarker for earlier detection of COVID-19 progression.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32424481|t=2020. Stages or phenotypes? A critical look at COVID-19 pathophysiology.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32424480|t=2020. Contrast-enhanced ultrasound (CEUS) of the lung reveals multiple areas of microthrombi in a COVID-19 patient.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32514592|t=2020. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32504103|t=2020. Ten things we learned about COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32494929|t=2020. COVID-19: 10 things I wished I'd known some months ago.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32494927|t=2020. Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32488341|t=2020. Rethinking the respiratory paradigm of COVID-19: a 'hole' in the argument.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533198|t=2020. Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32430651|t=2020. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32415560|t=2020. Bronchoalveolar lavage findings in severe COVID-19 pneumonia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399954|t=2020. SARS-CoV-2 and myocardial injury: a role for Nox2?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405622|t=2020. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32389590|t=2020. COVID-19: Unanswered questions on immune response and pathogenesis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425269|t=2020. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32422146|t=2020. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32422144|t=2020. Perforin and resistance to SARS coronavirus 2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32417135|t=2020. Complement activation in patients with COVID-19: A novel therapeutic target.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32413374|t=2020. Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437740|t=2020. The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32407836|t=2020. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531372|t=2020. Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32416206|t=2020. COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32417418|t=2020. Reply to: "Skin damage among health care workers managing coronavirus disease 2019".|pdf=|usr=008}}
| + | |
| − | {{tp|p=32498686|t=2020. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515358|t=2020. Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406037|t=2020. COVID-19: is fibrosis the killer?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473501|t=2020. Respirators used by healthcare workers due to the COVID-19 outbreak increase end-tidal carbon dioxide and fractional inspired carbon dioxide pressure.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32510470|t=2020. Is innate immunity our best weapon for flattening the curve?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32430154|t=2020. Hypolipidemia is associated with the severity of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32434770|t=2020. Predictive molecular pathology in the time of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32283335|t=2020. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32361326|t=2020. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32464309|t=2020. Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425659|t=2020. Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32451971|t=2020. Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32398780|t=2020. The role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32456973|t=2020. The novel coronavirus (COVID-19) and the risk of Kawasaki disease in children.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32366279|t=2020. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437830|t=2020. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32385146|t=2020. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32442454|t=2020. Which cancer type has the highest risk of COVID-19 infection?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32417316|t=2020. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32417310|t=2020. Characterization of eight novel full-length genomes of SARS-CoV-2 among imported COVID-19 cases from abroad in Yunnan, China.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526326|t=2020. Interleukin-6 as prognosticator in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32525000|t=2020. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534002|t=2020. Cancer population may be paradoxically protected from severe manifestations of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32283152|t=2020. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32283146|t=2020. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32360499|t=2020. Comparative seasonalities of influenza A, B and 'common cold' coronaviruses - setting the scene for SARS-CoV-2 infections and possible unexpected host immune interactions.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32283147|t=2020. Prolonged virus shedding even after seroconversion in a patient with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534944|t=2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32483488|t=2020. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454066|t=2020. High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32461703|t=2020. Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32383269|t=2020. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32383254|t=2020. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32383183|t=2020. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32410229|t=2020. Evidence of Increasing Diversification of Emerging SARS-CoV-2 Strains.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32406952|t=2020. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32401345|t=2020. Genetic variants and source of introduction of SARS-CoV-2 in South America.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32181903|t=2020. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32159234|t=2020. Identification of coronavirus sequences in carp cDNA from Wuhan, China.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519779|t=2020. Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32242950|t=2020. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32471659|t=2020. Silencing of immune activation with methotrexate in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534807|t=2020. Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32452979|t=2020. Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32392072|t=2020. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32463239|t=2020. Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32521376|t=2020. SARS-CoV-2 (Covid-19): Interferon-epsilon may be responsible of decreased mortality in females.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32514817|t=2020. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32525700|t=2020. Multi-System Inflammatory Syndrome in Children in Association with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32521002|t=2020. Antibody profiles in mild and severe cases of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522846|t=2020. ACE2 and COVID-19 and the resulting ARDS.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522874|t=2020. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32479986|t=2020. Type 3 hypersensitivity in COVID-19 vasculitis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32479985|t=2020. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473354|t=2020. Racial disparity in Covid-19 mortality rates - A plausible explanation.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32474885|t=2020. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32462425|t=2020. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399213|t=2020. Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32384917|t=2020. COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32456696|t=2020. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32456658|t=2020. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32414395|t=2020. COVID-19: room for treating T cell exhaustion?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32410690|t=2020. Age and sex differences in soluble ACE2 may give insights for COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32517773|t=2020. Systemic hypoferremia and severity of hypoxemic respiratory failure in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32499988|t=2020. Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32416074|t=2020. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32460144|t=2020. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522400|t=2020. Letter to the Editor on "Bonafe M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev".|pdf=|usr=008}}
| + | |
| − | {{tp|p=32513566|t=2020. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32475759|t=2020. IL-6: Relevance for immunopathology of SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32446778|t=2020. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32389499|t=2020. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32421092|t=2020. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32470851|t=2020. Role of oxidized LDL-induced "trained macrophages" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32417709|t=2020. Mechanism of inflammatory response in associated comorbidities in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32517769|t=2020. Histopathology of COVID-19 pneumonia in two non-oncological, non-hospitalised cases as a reliable diagnostic benchmark.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32412125|t=2020. Androgen sensitivity gateway to COVID-19 disease severity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454408|t=2020. COVID-19 as a STING disorder with delayed over-secretion of interferon-beta.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32393438|t=2020. Intelligent classification of platelet aggregates by agonist type.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529906|t=2020. Serological differentiation between COVID-19 and SARS infections.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529952|t=2020. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32525765|t=2020. Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515685|t=2020. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515684|t=2020. Patterns of IgG and IgM antibody response in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32380903|t=2020. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533508|t=2020. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32419876|t=2020. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32444797|t=2020. BBMRI-ERIC's contributions to research and knowledge exchange on COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32415272|t=2020. Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32404885|t=2020. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32376989|t=2020. The VODAN IN: support of a FAIR-based infrastructure for COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32335973|t=2020. Of mice and men: COVID-19 challenges translational neuroscience.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32444400|t=2020. COVID-19 and the nicotinic cholinergic system.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32398299|t=2020. To compare the incomparable: COVID-19 pneumonia and high altitude disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32432790|t=2020. Editorial - COVID-19 and the microbiota: new kids on the block.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32432787|t=2020. SARS-CoV-2 identification in lungs, heart and kidney specimens by transmission and scanning electron microscopy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32524957|t=2020. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32524946|t=2020. Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events, North-Rhine Westphalia, Germany, February and March 2020.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32474064|t=2020. A novel cell-based assay for dynamically detecting neutrophil extracellular traps-induced lung epithelial injuries.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454103|t=2020. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32489244|t=2020. Microthrombotic Complications of COVID-19 Are Likely Due to Embolism of Circulating Endothelial Derived Ultralarge Von Willebrand Factor (eULVWF) Decorated-Platelet Strings.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32399755|t=2020. A technical report from the Italian SARS-CoV-2 outbreak. Postmortem sampling and autopsy investigation in cases of suspected or probable COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425955|t=2020. Potential SARS-CoV-2 Preimmune IgM Epitopes.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425950|t=2020. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32391299|t=2020. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32442562|t=2020. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32413354|t=2020. Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437749|t=2020. Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32445924|t=2020. Overwhelming mutations or SNPs of SARS-CoV-2: A point of caution.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32510005|t=2020. COVID-19 target: A specific target for novel coronavirus detection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526937|t=2020. Analysis of the Hosts and Transmission Paths of SARS-CoV-2 in the COVID-19 Outbreak.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32520981|t=2020. ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32504168|t=2020. Impact of glycoscience in fighting Covid-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522249|t=2020. Genomics of COVID-19: molecular mechanisms going from susceptibility to severity of the disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437706|t=2020. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32483525|t=2020. A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32433946|t=2020. Herd Immunity: Understanding COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32392464|t=2020. SARS-CoV-2: Combating Coronavirus Emergence.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32497522|t=2020. Respiratory Virus Infections: Understanding COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32413330|t=2020. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534867|t=2020. Sequence homology between human PARP14 and the SARS-CoV-2 ADP ribose 1'-phosphatase.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32524333|t=2020. COVID 19: a clue from innate immunity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473952|t=2020. SARS-CoV-2: The viral shedding vs infectivity dilemma.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32509257|t=2020. SARS-CoV-2, "common cold" coronaviruses' cross-reactivity and "herd immunity": The razor of Ockham (1285-1347)?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32474891|t=2020. COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473977|t=2020. Unfolding SARS-CoV-2 viral genome to understand its gene expression regulation.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473976|t=2020. SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473352|t=2020. Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32450246|t=2020. Molecular epidemiology of SARS-CoV-2 in Faisalabad, Pakistan: A real-world clinical experience.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405281|t=2020. Sars-CoV-2 and black population: ACE2 as shield or blade?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32502733|t=2020. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32524515|t=2020. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32532942|t=2020. MERS-CoV and SARS-CoV infections in animals: a systematic review and meta-analysis of prevalence studies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529477|t=2020. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".|pdf=|usr=008}}
| + | |
| − | {{tp|p=32501423|t=2020. Developing an ultra-efficient microsatellite discoverer to find structural differences between SARS-CoV-1 and Covid-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531713|t=2020. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32437920|t=2020. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534186|t=2020. Procalcitonin levels in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32485251|t=2020. A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32516845|t=2020. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32530491|t=2020. Presepsin as a predictive biomarker of severity in COVID-19: A case series.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519791|t=2020. Hypoalbuminaemia in COVID-19 infection: A predictor of severity or a potential therapeutic target?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519786|t=2020. Pulmonary Capillary Leak Syndrome following COVID-19 Virus Infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32519768|t=2020. Hyperpyrexia in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526083|t=2020. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32530583|t=2020. Neuropathological Features of Covid-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534467|t=2020. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515386|t=2020. Glucovigilance in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32515374|t=2020. The Microbiology of Coronaviruses.|pdf=|usr=008}}
| + | |
| − | {{tp|p=31896597|t=2020. Host AAA+ ATPase TER94 Plays Critical Roles in Building the Baculovirus Viral Replication Factory and Virion Morphogenesis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32518411|t=2020. Genomic search for COVID-19 severity clues.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32514174|t=2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32528156|t=2020. Ten recommendations for supporting open pathogen genomic analysis in public health.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32528149|t=2020. Kawasaki disease in a COVID-19-struck region.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32427517|t=2020. COVID-19 Pandemic: Hopes from Proteomics and Multiomics Research.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533838|t=2020. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32527802|t=2020. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32467368|t=2020. Doctors race to understand inflammatory condition in kids.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32467367|t=2020. Scientists put survivors' blood plasma to the test.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32439770|t=2020. T cells found in coronavirus patients 'bode well' for long-term immunity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32527928|t=2020. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32527925|t=2020. Type III interferons disrupt the lung epithelial barrier upon viral recognition.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526773|t=2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32513613|t=2020. COVID-19 and the ABO blood group connection.|pdf=|usr=008}}
| + | |
| − | ===007===
| + | |
| − | '''some other papers''' | + | |
| − | {{tp|p=32496715|t=2020. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.]|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455617|t=2020. Novel Dynamic Structures of 2019-nCoV with Nonlocal Operator via Powerful Computational Technique.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512133|t=2020. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512089|t=2020. Corona virus versus existence of human on the earth: A computational and biophysical approach.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470223|t=2020. COVID-19: Structural Predictions of Viral Success.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423901|t=2020. How covid-19 is accelerating the threat of antimicrobial resistance.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32413176|t=2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504123|t=2020. COVID-19 research: toxicological input urgently needed!|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412787|t=2020. Bronchoscopy in COVID-19 Patients with Invasive Mechanical Ventilation: A Center Experience.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32213337|t=ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study |pdf=|usr=}}
| + | |
| − | {{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32360743|t=ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32292530|t=2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan|pdf=|usr=}}
| + | |
| − | {{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}}
| + | |
| − | {{tp|p=32348636|t=2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva |pdf=|usr=}}
| + | |
| − | {{tp|p=32235915|t=ä. COVID-19: a new challenge for human beings |pdf=|usr=}}
| + | |
| − | {{ttp|p=32359201|t=2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |pdf=|usr=}}
| + | |
| − | {{tp|p=32376309|t=2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32132669|t=ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32388390|t=2020. The powerful immune system against powerful COVID-19: A hypothesis |pdf=|usr=}}
| + | |
| − | {{tp|p=32372807|t=2020. The fever paradox |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32449057|t=2020. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32220035|t=2020. SARS-CoV-2: What do we know so far?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32534452|t=2020. From causes of aging to death from COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32339157|t=2020. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32489708|t=2020. Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32489698|t=2020. COVID-19 Virulence in Aged Patients Might Be Impacted by the Host Cellular MicroRNAs Abundance/Profile.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32401346|t=2020. SARS-CoV-2 immunogenicity at the crossroads.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32396996|t=2020. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32053148|t=2020. Three Emerging Coronaviruses in Two Decades.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32475764|t=2020. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32513452|t=2020. Abdominal pain in a patient with COVID-19 infection: A case of multiple thromboemboli.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32471782|t=2020. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32471783|t=2020. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425320|t=2020. Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32532619|t=2020. Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405074|t=2020. Visualization of SARS-CoV-2 virus invading the human placenta using electron microscopy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533928|t=2020. Letter-to-the-Editor: Alternative Interpretation to the Findings Reported in Visualization of SARS-CoV-2 Virus Invading the Human Placenta Using Electron Microscopy.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32391518|t=2020. Detection of SARS-COV-2 in Placental and Fetal Membrane Samples.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32427221|t=2020. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32471774|t=2020. SARS-CoV-2: Naso-bronchial cytological correlations.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32516444|t=2020. Immunological environment shifts during pregnancy may affect the risk of developing severe complications in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32439309|t=2020. Revision narrativa sobre la respuesta inmunitaria frente a coronavirus: descripcion general, aplicabilidad para SARS-COV-2 e implicaciones terapeuticas.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32505756|t=2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32505755|t=2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526061|t=2020. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32502135|t=2020. Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32458111|t=2020. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32414383|t=2020. Plasma CRP level is positively associated with the severity of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32387855|t=2020. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32462329|t=2020. Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32500224|t=2020. Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-a case report.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32495027|t=2020. Hematological findings in coronavirus disease 2019: indications of progression of disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529285|t=2020. SARS-CoV-2 infection in children with febrile neutropenia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529284|t=2020. Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32382776|t=2020. Signals of Th2 immune response from COVID-19 patients requiring intensive care.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32436075|t=2020. Microvascular alterations in patients with SARS-COV-2 severe pneumonia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32488505|t=2020. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32422085|t=2020. Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32527868|t=2020. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32395525|t=2020. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405117|t=2020. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32532524|t=2020. SARS-CoV-2-A Tough Opponent for the Immune System.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32493627|t=2020. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32471702|t=2020. Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32471703|t=2020. Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32419712|t=2020. COVID-19 and Dysfunctional Endothelium: The Mexican Scenario.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535095|t=2020. Molecular mimicry may explain multi-organ damage in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535093|t=2020. Covid-19 and autoimmunity.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32410735|t=2020. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32485205|t=2020. The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32479856|t=2020. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32480226|t=2020. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425294|t=2020. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32407552|t=2020. Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32529634|t=2020. Haemophagocytosis in bone marrow aspirates in patients with COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526046|t=2020. Secondary HLH is uncommon in severe COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32446945|t=2020. Do matrix metalloproteases mediate the SARS-CoV-2-related damage to the central nervous system?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454136|t=2020. The role of IgA in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32512702|t=2020. COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32479746|t=2020. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32492406|t=2020. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32416070|t=2020. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32413319|t=2020. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526206|t=2020. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526208|t=2020. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32516571|t=2020. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32473127|t=2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425270|t=2020. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405102|t=2020. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32514047|t=2020. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32513989|t=2020. The inhibition of IL-2/IL-2R gives rise to CD8(+) T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32499922|t=2020. ACE2 expression and sex disparity in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32485164|t=2020. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32464098|t=2020. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32415260|t=2020. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32398804|t=2020. Is aberrant CD8+ T cell activation by hypertension associated with cardiac injury in severe cases of COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32426212|t=2020. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531208|t=2020. Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32458383|t=2020. On barring the vascular gateway against severe COVID-19 disease.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32500379|t=2020. COVID-19 and heme oxygenase: novel insight into the disease and potential therapies.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454047|t=2020. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32417210|t=2020. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32405080|t=2020. Decreased T cell populations contribute to the increased severity of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531257|t=2020. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531256|t=2020. Cytokine Storm Induced by SARS-CoV-2.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32461193|t=2020. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526273|t=2020. A plea for the pathogenic role of immune complexes in severe Covid-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32407466|t=2020. An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32454188|t=2020. Correlation between viral RNA shedding and serum antibodies in individuals with coronavirus disease 2019.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32447048|t=2020. SARS-CoV-2 persisted in lung tissue despite disappearance in other clinical samples.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526483|t=2020. COVID 19 and brain crosstalks.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32525600|t=2020. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535877|t=2020. Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19).|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533690|t=2020. Placental Pathology in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32432897|t=2020. Reply: COVID-19 Lung Injury and "Typical" ARDS: The Danger of Presumed Equivalency.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32432896|t=2020. Respiratory Mechanics and Gas Exchange in COVID-19 Associated Respiratory Failure.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32432895|t=2020. COVID-19 Lung Injury and "Typical" ARDS: The Danger of Presumed Equivalency.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32434816|t=2020. Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32524832|t=2020. Is Albumin Predictor of Mortality in COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32531085|t=2020. C1-INH and the contact system in COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533986|t=2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526272|t=2020. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32533824|t=2020. Tuberculosis and type 2 Diabetes Mellitus: an inflammatory danger signal in the time of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32517505|t=2020. C3 polymorphisms represent an important immunological confounder on the spread and outcome of COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32518941|t=2020. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32522666|t=2020. How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526370|t=2020. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32525565|t=2020. Elevated expression of ACE2 in tumor-adjacent normal tissues of cancer patients.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32425712|t=2020. Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32535977|t=2020. Introductory histopathologic findings may shed light on COVID19 pediatric hyperinflammatory shock syndrome.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32513850|t=2020. Early Insights into Immune Responses during COVID-19.|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526012|t=2020. ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19.|pdf=|usr=008}}
| + | |
| − | | + | |
| − | {{tp|p=32515982|t=2020. H2S as a potential defence against COVID-19?|pdf=|usr=008}}
| + | |
| − | {{tp|p=32526026|t=2020. Hypersegmented granulocytes and COVID-19 infection.|pdf=|usr=008}}
| + | |
